Protagenic Therapeutics Statistics Share Statistics Protagenic Therapeutics has 868.41K
shares outstanding. The number of shares has increased by 0.44%
in one year.
Shares Outstanding 868.41K Shares Change (YoY) 0.44% Shares Change (QoQ) 4.28% Owned by Institutions (%) 14.16% Shares Floating 748.96K Failed to Deliver (FTD) Shares 16,276 FTD / Avg. Volume 7.25%
Short Selling Information The latest short interest is 10.9K, so 1.26% of the outstanding
shares have been sold short.
Short Interest 10.9K Short % of Shares Out 1.26% Short % of Float 1.36% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -6.08 and the forward
PE ratio is null.
Protagenic Therapeutics's PEG ratio is
3.5.
PE Ratio -6.08 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 33.18 P/FCF Ratio -7.97 PEG Ratio 3.5
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Protagenic Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2,
with a Debt / Equity ratio of 0.
Current Ratio 2 Quick Ratio 2 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-5.53M Employee Count 1 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -76.64% in the
last 52 weeks. The beta is 0.35, so Protagenic Therapeutics's
price volatility has been higher than the market average.
Beta 0.35 52-Week Price Change -76.64% 50-Day Moving Average 3.27 200-Day Moving Average 4.93 Relative Strength Index (RSI) 31.89 Average Volume (20 Days) 224,517
Income Statement
Revenue n/a Gross Profit n/a Operating Income -5.7M Net Income -5.53M EBITDA -5.47M EBIT -5.53M Earnings Per Share (EPS) -1.13
Full Income Statement Balance Sheet The company has 1.84M in cash and 0 in
debt, giving a net cash position of 1.84M.
Cash & Cash Equivalents 1.84M Total Debt n/a Net Cash n/a Retained Earnings -36.3M Total Assets 988.65K Working Capital -148.8K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -4.22M
and capital expenditures 0, giving a free cash flow of -4.22M.
Operating Cash Flow -4.22M Capital Expenditures n/a Free Cash Flow -4.22M FCF Per Share -0.86
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields PTIX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for PTIX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 5, 2025. It was a
backward
split with a ratio of 1:14.
Last Split Date May 5, 2025 Split Type backward Split Ratio 1:14
Scores Altman Z-Score -69.78 Piotroski F-Score 2
